- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.10. | Amgen and MediLink to collaborate on SCLC combination therapy | ||
| 08.10. | "Strategic market positioning" needed for Ebglyss to rival Dupixent in atopic dermatitis | ||
| 08.10. | Bayer and MOMA Therapeutics partner for oncology programme | ||
| 08.10. | MHRA puts technology in the spotlight in 2024/25 business plan | ||
| 08.10. | Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status | ||
| 08.10. | ViiV Healthcare to increase annual supply of long-acting HIV PrEP | ||
| 08.10. | Innovent and ASK Pharm to commercialise limertinib for lung cancer | ||
| 07.10. | Neuvivo makes bid to enter ALS arena with immunotherapy candidate | ||
| 07.10. | EMA starts review into hair loss drugs about potential link to suicidal thoughts | ||
| 07.10. | Oncolytics targets accelerated approval for oncolytic virus therapy | ||
| 07.10. | Activist investor Starboard forges $1bn stake in Pfizer to swing profits | ||
| 07.10. | ProductLife boosts drug development with IntiQuan acquisition | ||
| 07.10. | Health Canada approves Telix's Illuccix label expansion | ||
| 07.10. | OnKure and Reneo Pharmaceuticals complete merger | ||
| 07.10. | NUHS's CD7 CAR-T cell therapy shows promise for leukaemia | ||
| 07.10. | mRNA licensing agreements double with million-dollar deals | ||
| 04.10. | FDA lifts clinical hold on Avidity's lead antibody conjugate therapy trial | ||
| 04.10. | NHS proposes phased launch for Eli Lilly's Mounjaro | ||
| 04.10. | Recordati to acquire worldwide rights to Sanofi's antibody Enjaymo | ||
| 04.10. | Teva and mAbxience partner to develop biosimilar candidate for oncology | ||
| 04.10. | BMS receives FDA approval for Opdivo to treat NSCLC | ||
| 04.10. | Resilience secures funds to enhance production of essential medicine components | ||
| 03.10. | Resolution scores $83m to develop macrophage cell therapies | ||
| 03.10. | Chronic diseases "as urgent as climate change," says Novo Nordisk CSO | ||
| 03.10. | Enara Bio secures $32.5m for 'Dark Antigen' cancer therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
